Boehringer Ingelheim has licensed Vectron Biosolutions' expression technology platform.This non-exclusive license agreement comes as a result of a successful joint feasibility study between the two companies in which Vectron's proprietary genetic elements were tested for high-yield, soluble production of a protein of interest to Boehringer Ingelheim in Escherichia coli. This agreement gives Boehringer Ingelheim the right to use Vectron's technology for both production of biopharmaceutical products from its own in-house pipeline and as part of the Boehringer Ingelheim BioXcellence offerings in contract manufacturing.

Vectron Biosolutions was founded in 2008 based on the expression vector technology developed in Professor Svein Valla's research group at the Norwegian University of Science and Technology, in Trondheim, Norway. The company offers research and development services using its proprietary expression technology platform that has been developed for production of proteins in E. coli and other bacteria. This modular technology is comprised of vector backbones and genetic libraries of Pm promoters, xylS transcription regulators, 5'-UTRs, and signal peptides. Using combinations of these elements, it is possible to design expression vectors that are optimized for high-yield, soluble expression of numerous proteins in E. coli and in other bacteria. Vectron Biosolutions is a privately owned company.

Source: Boehringer Ingelheim